| Keryx Completes Enrolment In Long-Term Phase III Study Of Zerenex - RTT News |
|
|
RTT News Zerenex is the the company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. This Phase 3 long-term study is a multicenter, ... Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex |